昆药集团：公司将持续推进相关药品说明书安全信息的修订，目标在2030年前完成

Core Viewpoint - The company is actively working on revising safety information in traditional Chinese medicine product labels and aims to complete the re-registration of all its products by 2030 [2] Group 1: Product Safety Information Revision - The company has developed a plan for revising safety information in traditional Chinese medicine product labels in 2023 and is making progress according to this plan [2] - The safety information revision for the product "Dandelion Granules" has been completed, while the revision for "Qi Ju Di Huang Wan" is currently underway [2] Group 2: Re-registration and Compliance - The company successfully completed the re-registration of all 143 approved drug licenses by 2025 and will continue to push for the revision of safety information in product labels [2] - The goal is to complete this work before the next re-registration cycle in 2030 and to obtain the necessary re-registration approvals [2] Group 3: Market Strategy and Product Distribution - In recent years, the company has been focusing on channel restructuring and brand building, with a particular emphasis on promoting products in chain terminals [2] - The company is continuously optimizing its retail channel layout across the country to enhance the market circulation efficiency of its products [2]